GO:0002470 plasmacytoid dendritic cell antigen processing and presentation: Immune Surveillance Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002470 describes the biological process by which plasmacytoid dendritic cells (pDCs) express antigen on their surface in association with MHC protein complexes.
• pDCs are a specialized dendritic cell subset that bridge innate sensing of nucleic acids with adaptive T cell priming.
• Antigen processing in dendritic cells involves uptake, proteolytic degradation, and loading of peptides onto MHC class I or class II molecules.
• pDC antigen presentation is critical for antiviral immunity and for shaping tolerance versus autoimmunity.
• Dysregulation of pDC antigen presentation is implicated in autoimmune diseases such as psoriasis and systemic lupus erythematosus.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of genes controlling pDC antigen presentation.
Description
Plasmacytoid dendritic cells (pDCs) are a unique dendritic cell subset specialized for rapid production of type I interferons in response to viral nucleic acids, but they also function as antigen-presenting cells that can prime T cell responses. The Gene Ontology term GO:0002470, plasmacytoid dendritic cell antigen processing and presentation, captures the process by which pDCs express antigen (peptide or lipid) on their cell surface in association with an MHC protein complex. This process is fundamental to linking innate nucleic acid sensing to adaptive immunity and to maintaining immune homeostasis. Researchers study GO:0002470 to understand how pDCs contribute to antiviral defense, tumor immunosurveillance, and the pathogenesis of autoimmune diseases. Antigen processing and presentation by dendritic cells requires coordinated vesicular trafficking, proteolysis, and MHC loading, all of which are regulated by cell-type-specific factors. Because pDCs are a rare population, genetic tools such as CRISPR knockout and knock-in models are essential to determine which genes causally control this process. This article provides a research-grade overview of GO:0002470, including its definition, molecular players, disease relevance, and experimental strategies for interrogation using CRISPR-based cell models and functional genomics.
plasmacytoid dendritic cell antigen processing and presentation At A Glance
| GO ID | GO:0002470 |
|---|---|
| GO term | plasmacytoid dendritic cell antigen processing and presentation |
| Ontology | biological_process |
| Synonym | None |
| Major function | Expression of antigen on the pDC surface in association with MHC protein complexes for T cell recognition |
| Cell type | Plasmacytoid dendritic cells (pDCs) |
| MHC classes involved | MHC class I and MHC class II |
| Related processes | Antigen uptake, proteolysis, MHC loading, vesicular trafficking |
| Disease relevance | Autoimmunity, antiviral immunity, cancer immunosurveillance |
What Is GO:0002470?
GO:0002470 is defined as the process in which a plasmacytoid dendritic cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex. This encompasses antigen uptake, intracellular processing, and surface presentation specifically within the pDC lineage, distinguishing it from antigen presentation by conventional dendritic cells or other antigen-presenting cells.
Why Is plasmacytoid dendritic cell antigen processing and presentation Important in Cell Biology?
GO:0002470 is important because pDCs are a key interface between innate nucleic acid sensing and adaptive T cell immunity, and their antigen presentation capacity influences outcomes in viral infection, autoimmunity, and cancer. Understanding this process at the molecular level can reveal therapeutic targets for modulating immune responses.
• pDCs are major producers of type I interferons and also present antigen to T cells, linking innate and adaptive immunity.
• Antigen processing and presentation by dendritic cells is essential for initiating and regulating T cell responses.
• pDC antigen presentation contributes to antiviral immunity by priming virus-specific T cells.
• Dysregulated pDC antigen presentation is associated with autoimmune diseases such as systemic lupus erythematosus and psoriasis.
• pDCs can present tumor antigens and influence anti-tumor immunity.
• MHC class I and class II pathways in pDCs are regulated by distinct molecular machinery.
• Understanding pDC-specific antigen presentation may improve vaccine design.
• CRISPR screens can identify genes required for pDC antigen presentation.
• pDC antigen presentation is relevant to transplantation tolerance and graft-versus-host disease.
• Single-cell and imaging methods enable study of rare pDC populations.
What Happens During plasmacytoid dendritic cell antigen processing and presentation?
Antigen uptake and sensing
In simple terms: pDCs take up antigens from their environment and sense nucleic acids.
Plasmacytoid dendritic cells capture exogenous antigens through endocytosis, phagocytosis, and receptor-mediated uptake, and they sense viral or self nucleic acids via innate receptors. This uptake step is a prerequisite for subsequent processing and presentation on MHC molecules.
Antigen processing and peptide generation
In simple terms: The taken-up proteins are cut into peptides inside the cell.
Internalized antigens are delivered to endosomal and lysosomal compartments where proteases degrade them into peptides suitable for loading onto MHC class II molecules, while cytosolic antigens are processed by the proteasome for MHC class I presentation. Dendritic cells, including pDCs, possess specialized cell biological mechanisms for antigen processing.
MHC loading and surface presentation
In simple terms: Peptides are loaded onto MHC molecules and displayed on the cell surface.
Peptides generated during processing are loaded onto MHC class I or class II molecules in dedicated compartments, and the peptide-MHC complexes are then transported to the plasma membrane for recognition by T cell receptors. This surface expression of antigen in association with MHC protein complexes is the defining output of GO:0002470.
Co-stimulation and T cell priming
In simple terms: pDCs provide additional signals to activate T cells.
Beyond peptide-MHC presentation, pDCs express co-stimulatory molecules and secrete cytokines that shape T cell activation and differentiation. The integration of antigen presentation with co-stimulation determines whether T cells become activated, tolerant, or exhausted.
Regulation by innate sensing pathways
In simple terms: Nucleic acid sensing can boost or modulate antigen presentation.
In pDCs, nucleic acid sensing pathways can influence antigen processing and presentation efficiency, linking innate immune activation to adaptive immune priming. This regulation ensures that antigen presentation is context-dependent and responsive to infection or danger signals.
Key Genes Involved in GO:0002470 plasmacytoid dendritic cell antigen processing and presentation
The following genes and proteins are central to plasmacytoid dendritic cell antigen processing and presentation, based on their established roles in antigen uptake, processing, MHC loading, and pDC biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-A | MHC class I heavy chain; presents endogenous peptides to CD8+ T cells | Target for knockout to study MHC class I presentation in pDCs |
| HLA-B | MHC class I heavy chain; presents peptides to CD8+ T cells | Knockout models to assess pDC antigen presentation |
| HLA-C | MHC class I heavy chain; presents peptides to NK and T cells | Relevant to pDC-mediated immune regulation |
| HLA-DRA | MHC class II alpha chain; presents exogenous peptides to CD4+ T cells | Knockout to study MHC class II presentation in pDCs |
| HLA-DRB1 | MHC class II beta chain; peptide presentation to CD4+ T cells | Disease-associated allele in autoimmunity |
| B2M | Beta-2-microglobulin; essential for MHC class I surface expression | Common knockout target to abolish MHC class I presentation |
| TAP1 | Transporter associated with antigen processing; delivers peptides to MHC class I | Knockout reduces MHC class I peptide loading |
| TAP2 | Transporter associated with antigen processing; peptide transport | Knockout models for antigen processing defects |
| PSMB8 | Immunoproteasome subunit; generates peptides for MHC class I | Point mutation and knockout studies |
| PSMB9 | Immunoproteasome subunit; peptide generation | Relevant to pDC antigen processing |
| CTSS | Cathepsin S; MHC class II peptide loading | Knockout affects MHC class II presentation |
| CTSL | Cathepsin L; antigen degradation | Knockout models for lysosomal processing |
| LAMP1 | Lysosomal marker; antigen processing compartment | Tagged knock-in for imaging |
| CD74 | MHC class II invariant chain; regulates peptide loading | Knockout alters MHC class II presentation |
| CLEC4C | pDC-specific C-type lectin; antigen uptake | pDC marker and uptake receptor |
| TLR7 | Nucleic acid sensor; links innate sensing to pDC activation | Knockout affects pDC function |
| TLR9 | Nucleic acid sensor; pDC activation | Knockout models for pDC biology |
| IRF7 | Transcription factor; type I interferon production in pDCs | Knockout impacts pDC-mediated immunity |
How Is plasmacytoid dendritic cell antigen processing and presentation Regulated?
Antigen processing and presentation in pDCs is regulated by innate immune sensing pathways, cytokine signals, and transcriptional programs that control MHC expression and vesicular trafficking. For example, nucleic acid sensing through TLR7 and TLR9 can modulate pDC activation and antigen presentation capacity. Additionally, the cellular machinery for MHC class I and class II presentation is subject to regulation by proteolytic activity and peptide transporter availability. However, specific mTOR or ISR control of GO:0002470 in pDCs is not well defined in the provided literature, and further studies are needed to establish direct regulatory links.
plasmacytoid dendritic cell antigen processing and presentation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HLA-DRB1 | Autoimmunity (e.g., lupus, rheumatoid arthritis) | Knock-in of risk alleles in pDC-like cell lines |
| B2M | Defective MHC class I presentation; cancer immune evasion | Knockout in pDC models to abolish MHC class I |
| TLR7 | Systemic lupus erythematosus; pDC activation | Knockout or point mutation to study nucleic acid sensing |
| TLR9 | Autoimmunity and antiviral immunity | Knockout in pDC models |
| IRF7 | Impaired type I interferon responses | Knockout to assess pDC function |
Autoimmune diseases
Dysregulated pDC antigen presentation and type I interferon production are implicated in autoimmune diseases such as systemic lupus erythematosus and psoriasis, where pDCs can present self-antigens and promote autoreactive T cell responses. Understanding GO:0002470 may reveal targets for modulating autoimmunity.
Viral infections
pDCs are critical for antiviral immunity, and their ability to process and present viral antigens contributes to the priming of virus-specific T cells. Defects in antigen presentation could impair viral clearance.
Cancer
pDCs can present tumor antigens and influence anti-tumor immunity, and enhancing pDC antigen presentation is a potential strategy for cancer immunotherapy. Recent studies highlight the role of extracellular vesicle DNA transfer in enhancing antigen presentation and anti-tumor immunity.
From plasmacytoid dendritic cell antigen processing and presentation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is gene X required for pDC antigen presentation? | CRISPR knockout in pDC cell line or primary pDCs |
| Does a disease-associated point mutation alter MHC loading? | Point mutation knock-in via CRISPR |
| How does a tagged MHC molecule traffic in pDCs? | Knock-in of fluorescent tag (e.g., GFP) on HLA gene |
| Does overexpression of gene Y enhance antigen presentation? | CRISPR activation or lentiviral overexpression |
| Which genes regulate pDC antigen presentation in a genome-wide manner? | CRISPR library screening |
| Can we visualize peptide-MHC complexes on pDCs? | Tagged knock-in and imaging |
How to Study the plasmacytoid dendritic cell antigen processing and presentation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface peptide-MHC complexes | Quantify antigen presentation after gene knockout |
| Immunopeptidomics | Peptide sequences bound to MHC | Identify peptide repertoire changes |
| Confocal microscopy | Localization of MHC and antigens | Study vesicular trafficking in pDCs |
| CRISPR knockout screening | Gene requirement for antigen presentation | Discover novel regulators |
| RNA-seq | Transcriptional changes in pDCs | Assess MHC and processing gene expression |
| Western blot | Protein expression of MHC and processing enzymes | Validate knockout efficiency |
| ELISPOT | T cell activation by presented antigen | Functional readout of antigen presentation |
| Tetramer staining | Antigen-specific T cell frequency | Assess priming capacity of pDCs |
Flow cytometry and MHC tetramer staining
Flow cytometry with MHC tetramers or antibodies against peptide-MHC complexes allows quantification of antigen presentation on pDC surfaces. This method is widely used to assess functional outcomes of genetic perturbations.
Proteomics and immunopeptidomics
Mass spectrometry-based immunopeptidomics identifies peptides presented on MHC molecules, providing a direct readout of antigen processing. This approach can reveal how genetic changes alter the peptide repertoire.
Imaging of antigen processing compartments
Confocal and super-resolution microscopy with tagged MHC or lysosomal markers enables visualization of antigen processing and loading events in pDCs. Live-cell imaging can track vesicular trafficking.
CRISPR screens and functional genomics
Genome-wide CRISPR knockout or activation screens coupled with MHC presentation readouts can identify novel regulators of pDC antigen presentation. These screens are powerful for discovering genes with previously unknown roles.
How CRISPR Can Be Used to Study GO:0002470 plasmacytoid dendritic cell antigen processing and presentation
Knockout
CRISPR knockout of candidate genes such as B2M, TAP1, or HLA-DRA in pDC models can abolish or reduce antigen presentation, providing causal evidence for their role in GO:0002470. Knockout studies are essential to distinguish necessary from redundant factors.
Point Mutation
Introducing disease-associated point mutations (e.g., in HLA-DRB1 or TLR7) via CRISPR base editing or homology-directed repair allows assessment of how specific variants affect pDC antigen presentation. This approach links genetic variants to functional outcomes.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) on MHC or processing genes enables real-time imaging of antigen presentation in live pDCs. Tagged knock-in models are valuable for tracking protein trafficking and localization.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase expression of genes hypothesized to enhance antigen presentation, allowing gain-of-function studies. Overexpression models help identify sufficiency relationships.
How EDITGENE Supports plasmacytoid dendritic cell antigen processing and presentation Research
Researchers studying plasmacytoid dendritic cell antigen processing and presentation-related genes often need to determine whether a candidate gene is causally involved in MHC loading, surface presentation, or T cell priming. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for plasmacytoid dendritic cell antigen processing and presentation research.
Frequently Asked Questions About plasmacytoid dendritic cell antigen processing and presentation
What is GO:0002470?
GO:0002470 is the Gene Ontology term for plasmacytoid dendritic cell antigen processing and presentation, the process by which pDCs express antigen on their surface in association with MHC protein complexes.
What genes are involved in plasmacytoid dendritic cell antigen processing and presentation?
Key genes include MHC class I and II genes (HLA-A, HLA-B, HLA-DRA, HLA-DRB1), B2M, TAP1, TAP2, PSMB8, PSMB9, CTSS, CD74, CLEC4C, TLR7, TLR9, and IRF7.
How do plasmacytoid dendritic cells present antigen?
pDCs take up antigens, process them into peptides, load them onto MHC molecules, and present the peptide-MHC complexes on their surface to T cells.
Why is pDC antigen presentation important?
It bridges innate nucleic acid sensing with adaptive T cell immunity and is critical for antiviral defense, autoimmunity, and cancer immunosurveillance.
What diseases are associated with pDC antigen presentation?
Autoimmune diseases like lupus and psoriasis, viral infections, and cancer are associated with pDC antigen presentation.
How can I study pDC antigen presentation using CRISPR?
CRISPR knockout, knock-in, point mutation, and overexpression models in pDC cell lines or primary cells can be used to dissect gene function.
What methods measure antigen presentation in pDCs?
Flow cytometry, immunopeptidomics, microscopy, and T cell activation assays are commonly used.
What is the role of MHC class I in pDC antigen presentation?
MHC class I presents endogenous peptides to CD8+ T cells and is essential for antiviral and anti-tumor immunity.
What is the role of MHC class II in pDC antigen presentation?
MHC class II presents exogenous peptides to CD4+ T cells and is important for priming helper T cell responses.
Can EDITGENE help create pDC models for antigen presentation research?
Yes, EDITGENE offers knockout, point mutation, knock-in, overexpression, and CRISPR library screening services for pDC antigen presentation research.
Conclusion
GO:0002470, plasmacytoid dendritic cell antigen processing and presentation, is a specialized biological process that connects innate nucleic acid sensing to adaptive immunity. Understanding its molecular players and regulation is essential for developing therapies for autoimmune diseases, viral infections, and cancer. CRISPR-based cell models and functional genomics provide powerful tools to dissect this process and identify new therapeutic targets.
References
- 1. Mellman I et al.. 2010. Antigen processing and presentation.. Curr Opin Immunol 22(1):78-80 PMID: 20172702
- 2. Neefjes J et al.. 2011. Towards a systems understanding of MHC class I and MHC class II antigen presentation.. Nat Rev Immunol 11(12):823-36 PMID: 22076556
- 3. Reis e Sousa C et al.. 2014. Antigen processing.. Curr Opin Immunol 26:138-9 PMID: 24556410
- 4. Kotsias F et al.. 2019. Antigen processing and presentation.. Int Rev Cell Mol Biol 348:69-121 PMID: 31810556
- 5. Steinman RM et al.. 1999. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies.. Hum Immunol 60(7):562-7 PMID: 10426272
- 6. Hu M et al.. 2026. Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity.. Cancer Cell 44(5):965-982.e12 PMID: 42066762
- 7. Macri C et al.. 2018. Dendritic cell subsets.. Semin Cell Dev Biol 84:11-21 PMID: 29246859
- 8. Mellman I. 2005. Antigen processing and presentation by dendritic cells: cell biological mechanisms.. Adv Exp Med Biol 560:63-7 PMID: 15932021
